

GUFIC BIOSCIENCES LIMITED


Regd office : 2nd Floor, Building A, Moti Baug, 118/119, S.V.Road, Andheri(West), Mumbai-400 058

UNAUDITED FINANCIAL (PROVISIONAL) RESULTS FOR THE QUARTER ENDED 30.09.2012

Particulars	Rs. In Lacs					
	Quarter Ended 30.09.2012 Unaudited	Quarter Ended 30.06.2012 Unaudited	Quarter Ended 30.09.2011 Unaudited	For the Period Ended 30.09.2012 Unaudited	For the Period Ended 30.09.2011 Unaudited	For the Year Ended 31.03.2012 Audited
INCOME:						
Net Sales / Income from Operations (Net of Excise Duty)	2370.31	2714.01	2032.28	5084.32	3980.21	8341.16
Other Operating Income	4.88	9.12	2.68	14.00	6.88	39.92
Total Income from Operations (Net)	2375.20	2723.12	2034.96	5098.32	3987.09	8381.08
EXPENSES:						
Cost of Materials Consumed	1011.58	869.23	579.19	1880.81	1386.51	2588.85
Purchase of Stock-in-Trade	373.10	423.46	466.94	796.56	783.00	1953.39
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(413.20)	269.73	46.55	(143.47)	(10.27)	(46.22)
Employee Benefits Expenses	126.71	112.07	120.51	238.78	218.89	460.28
Depreciation and Amortisation Expenses	51.64	51.00	53.80	102.64	100.00	188.12
Other Expenses	1011.00	800.33	635.68	1811.33	1222.20	2688.78
Total Expenses	2160.84	2525.83	1902.67	4686.67	3700.33	7833.20
Profit from Operations before Other Income, finance costs and Exceptional Items	214.36	197.29	132.29	411.65	286.76	547.88
Other Income	0.48	0.15	0.56	0.63	0.74	12.20
Profit from ordinary activities before finance costs and exceptional items	214.83	197.45	132.85	412.28	287.50	560.08
Finance Costs	78.72	62.61	61.17	141.33	126.25	263.07
Profit from ordinary activities after finance costs but before exceptional items	136.11	134.84	71.68	270.95	161.25	297.01
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
Profit from Ordinary Activities Before Tax	136.11	134.84	71.68	270.95	161.25	297.01
Tax Expenses	47.25	47.25	25.00	94.50	57.00	144.30
Net Profit from Ordinary Activities After Tax	88.86	87.59	46.68	176.45	104.25	152.71
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit for the Period	88.86	87.59	46.68	176.45	104.25	152.71
Paid up Equity Share Capital (Face Value of Rs 1 /- Each)	773.50	773.50	773.50	773.50	773.50	773.50
Reserves Excluding Revaluation Reserves	1354.39	1265.51	1174.41	1354.39	1174.41	1177.92
E.P.S	0.11	0.11	0.06	0.23	0.13	0.20
Public Shareholding						
-- Number of Shares of Rs 1 /- Each	23222355	23222337	23222337	23222355	23222337	23222337
-- Percentage of shareholding	30.02%	30.15%	30.15%	30.02%	30.15%	30.15%
Promoters and Promoter group Shareholding						
a) Pledged / Encumbered						
-- Number of Shares of Rs 1 /- Each	0	0	0	0	0	0
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
-- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non - Encumbered						
-- Number of Shares of Rs 1 /- Each	54127645	54027663	54027663	54127645	54027663	54027663
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
-- Percentage of Shareholding on total Capital of the company	69.98%	69.85%	69.85%	69.98%	69.85%	69.85%

The above Results were reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 9th November, 2012 and a limited review of the same has been carried out by the Statutory Auditors of the Company.

For GUFIC BIOSCIENCES LTD.


 Pranav J. Choksi
 Ex. Director

 Place: Mumbai
 Date: 09.11.2012

UNAUDITED (PROVISIONAL) SEGMENT WISE RESULTS

Particulars	Quarter Ended	Quarter Ended	Quarter Ended	For the	For the	For the
	30.09.2012 Unaudited	30.06.2012 Unaudited	30.09.2011 Unaudited	Period Ended 30.09.2012 Unaudited	Period Ended 30.09.2011 Unaudited	Year Ended 31.03.2012 Audited
SEGMENT REVENUE						
Sales & Service						
Pharma	2161.06	2403.16	1865.65	4564.22	3673.31	7670.26
Consumer	209.25	310.85	166.63	520.10	306.90	670.90
Total	2370.31	2714.01	2032.28	5084.32	3980.21	8341.16
Unallocated Income	5.36	9.27	3.24	14.63	7.62	52.12
Total Segment Revenue	2375.67	2723.28	2035.52	5098.95	3987.83	8393.28
SEGMENT RESULTS						
Pharma	419.01	465.95	351.68	884.96	694.77	1487.19
Consumer	40.48	60.13	31.17	100.61	57.39	129.78
TOTAL	459.49	526.08	382.85	985.57	752.16	1616.97
Less: Unallocated over heads	193.01	277.63	196.20	470.64	364.66	868.78
Finance Charges	78.72	62.61	61.17	141.33	126.25	263.07
Depreciation	51.64	51.00	53.80	102.64	100.00	188.12
Tax provision	47.25	47.25	25.00	94.50	57.00	144.30
Net Profit after Tax	88.86	87.59	46.68	176.45	104.25	152.71

UNAUDITED STATEMENT OF ASSETS AND LIABILITIES

Particulars	Rs. in Lacs	
	AS AT 30.09.2012 Unaudited	AS AT 31.03.2012 Audited
EQUITY AND LIABILITIES		
Shareholder's Funds		
a) Share Capital	773.50	773.50
b) Reserves and Surplus	1354.39	1177.92
Sub-total - Shareholder's Funds	2127.89	1951.42
Non-current liabilities		
a) Long-term borrowings	759.01	431.80
b) Deferred tax liabilities (Net)	241.50	241.50
c) Other long-term liabilities	112.02	101.50
d) Long-term provisions	126.63	99.73
Sub-total - Non-current liabilities	1239.16	874.53
Current liabilities		
a) Short-term borrowings	1629.18	1531.97
b) Trade payables	2441.66	2221.56
c) Other current liabilities	1057.70	642.28
d) Short-term provisions	217.50	191.02
Sub-total - Current liabilities	5346.04	4586.83
TOTAL - EQUITY AND LIABILITIES	8713.09	7412.78
ASSETS		
Non-current assets		
a) Fixed assets	2138.77	1877.59
b) Non-current investments	0.92	0.92
c) Long-term loans and advances	762.80	548.86
d) Other non-current assets	0.47	5.18
Sub-total - Non-Current assets	2902.96	2432.55
Current assets		
a) Current investments	0.00	0.00
b) Inventories	1771.79	1690.94
c) Trade receivables	2844.88	2257.15
d) Cash and cash equivalents	144.62	96.27
e) Short-term loans and advances	1013.78	860.86
f) Other current assets	35.05	75.01
Sub-total - Non-Current assets	5810.13	4980.23
TOTAL - ASSETS	8713.09	7412.78

The above Results were reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 9th November, 2012 and a limited review of the same has been carried out by the Statutory Auditors of the Company.

Investors Complaints received and disposed off during the Quarter Ended 30th September, 2012.

Nos

Complaints Pending at the Beginning of the quarter
 Complaints received during the quarter
 Disposal of Complaints
 Complaints lying unresolved at the end of the quarter

Nil
 Nil
 Nil
 Nil

Previous periods' figures have been regrouped, rearranged, reworked or reclassified wherever necessary to confirm to the current periods' classification

For GUFIC BIOSCIENCES LTD.

Pranav J Choksi
 Ex. Director

Date: 09.11.2012
 Place: Mumbai